NCT04948762

Brief Summary

Minimally-invasive surgery (MIS) techniques have revolutionised the approach to rectal cancer surgery. With increasing experience, surgeons have began to utilise these platforms increasingly in the context of pelvic exenteration (PE). This observational retrospective review plans to assess the volume of PE being performed on a global basis and to assess the comparative outcomes associated with each technique in order to assess the optimal approach to radical pelvic surgery.

Trial Health

43
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
1,000

participants targeted

Target at P75+ for all trials

Timeline
Completed

Started Aug 2021

Shorter than P25 for all trials

Geographic Reach
1 country

1 active site

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

June 24, 2021

Completed
8 days until next milestone

First Posted

Study publicly available on registry

July 2, 2021

Completed
1 month until next milestone

Study Start

First participant enrolled

August 1, 2021

Completed
4 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

December 1, 2021

Completed
2 months until next milestone

Study Completion

Last participant's last visit for all outcomes

February 1, 2022

Completed
Last Updated

October 20, 2021

Status Verified

October 1, 2021

Enrollment Period

4 months

First QC Date

June 24, 2021

Last Update Submit

October 12, 2021

Conditions

Outcome Measures

Primary Outcomes (1)

  • Resection status

    Completeness of the surgical resection (R0, R1 or R2)

    July 2016 - July 2021

Secondary Outcomes (7)

  • Blood loss

    July 2016 - July 2021

  • Operation time

    July 2016 - July 2021

  • Conversion rate

    July 2016 - July 2021

  • Morbidity

    July 2016 - July 2021

  • Length of stay

    July 2016 - July 2021

  • +2 more secondary outcomes

Study Arms (3)

Open

Patients who underwent an open approach to pelvic exenteration

Laparoscopic

Patients who underwent a laparoscopic approach to pelvic exenteration

Robotic

Patients who underwent a robotically-assisted pelvic exenteration

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

Patients over 18 years of age who are undergoing surgery for histologically-confirmed locally advanced or recurrent rectal cancer.

You may qualify if:

  • Histologically proven locally advanced or recurrent RECTAL cancer
  • Aged over 18 years
  • Undergoing a multi-visceral extended pelvic resection
  • Procedure took place within the specified timeframe (July 2016 - July 2021)

You may not qualify if:

  • Extra-pelvic/ non-resectable metastatic or peritoneal disease
  • Palliative pelvic exenteration
  • Insufficient patient follow-up data

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

St. Vincent's Hospital

Dublin, D4, Ireland

RECRUITING

Study Officials

  • Desmond Winter, MD

    St. Vincent's Healthcare Group

    STUDY CHAIR

Central Study Contacts

Matthew Fahy, MD

CONTACT

Michael Kelly, MD

CONTACT

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
RETROSPECTIVE
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Professor Desmond C Winter

Study Record Dates

First Submitted

June 24, 2021

First Posted

July 2, 2021

Study Start

August 1, 2021

Primary Completion

December 1, 2021

Study Completion

February 1, 2022

Last Updated

October 20, 2021

Record last verified: 2021-10

Locations